Replimune Group, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$209.02M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REPL stock price vs CIEN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CIEN's multiple
Needs Revenue / share, CIEN P/S.
Implied fair value · at REPL's multiple
Needs REPL P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REPLIMUNE GROUP, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Ciena Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe REPL can materially improve profitability and quality from its current weak base, then a selective hold or small speculative position may make sense because the stock is only mid-range versus its historical band; otherwise, the current data favor caution because REPL’s losses and 1/9 Piotroski score do not support a strong relative-value case.
No direct P/S or implied-price comparison is available for REPL, so the valuation gap cannot be quantified on a like-for-like revenue basis. REPL does trade inside its stated historical band at $11.58, which is between the $10.42 low and $12.74 high, suggesting the stock is not at an obvious valuation extreme from the provided range.
Supporting Metrics